Literature DB >> 3672573

Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication.

B Rambeck1, T May, U Juergens.   

Abstract

The influence of carbamazepine (CBZ) dose, CBZ preparation used, comedication (phenobarbital, phenytoin, primidone, valproate), and factors such as age, weight, and sex on the concentration of CBZ and its metabolites carbamazepine-10,11-epoxide (CBZ-epoxide) and 10,11-dihydro-10,11-dihydroxy-carbamazepine (CBZ-diol) in serum was investigated. A non-linear regression analysis using the data of 609 patients shows that other anti-epileptic drugs can influence the metabolism of CBZ in various ways. The mean serum concentration of CBZ is lower when the drug is given in combination with phenytoin (59.4%), primidone (58.2%), phenobarbital (65.7%), and valproate (83.0%) than when CBZ is given alone (100%), whereas the mean concentration of CBZ-epoxide is increased by valproate (144.8%), by primidone (118.5%), and by a combination of the latter (167.4%). The CBZ-diol concentrations are also increased during concomitant treatment with the other antiepileptic drugs. Our results indicate a nonlinear relationship between the CBZ dose and the CBZ concentration, but a linear relationship between the CBZ dose and the CBZ-diol concentration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3672573     DOI: 10.1097/00007691-198709000-00008

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

1.  Population pharmacokinetics of carbamazepine in elderly patients.

Authors:  Baralee Punyawudho; Eugene R Ramsay; Richard C Brundage; Flavia M Macias; Joseph F Collins; Angela K Birnbaum
Journal:  Ther Drug Monit       Date:  2012-04       Impact factor: 3.681

Review 2.  Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.

Authors:  R Riva; F Albani; M Contin; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

3.  SCN1A splice variants exhibit divergent sensitivity to commonly used antiepileptic drugs.

Authors:  Christopher H Thompson; Kristopher M Kahlig; Alfred L George
Journal:  Epilepsia       Date:  2011-03-31       Impact factor: 5.864

4.  Population pharmacokinetics of carbamazepine in Singapore epileptic patients.

Authors:  E Chan; H S Lee; S S Hue
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

5.  Carbamazepine clearance in paediatric epilepsy patients. Influence of body mass, dose, sex and co-medication.

Authors:  B Summers; R S Summers
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

6.  Daily variations in steady-state plasma concentrations of carbamazepine and its metabolites in epileptic children.

Authors:  R Hartley; W I Forsythe; B McLain; P C Ng; M D Lucock
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 7.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 8.  Antiepileptic drugs. A review of clinically significant drug interactions.

Authors:  P N Patsalos; J S Duncan
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

9.  The effect of pioglitazone on pharmacokinetics of carbamazepine in healthy rabbits.

Authors:  Issam Abushammala
Journal:  Saudi Pharm J       Date:  2014-07-08       Impact factor: 4.330

10.  Specific safety and tolerability considerations in the use of anticonvulsant medications in children.

Authors:  Amy Z Crepeau; Brian D Moseley; Elaine C Wirrell
Journal:  Drug Healthc Patient Saf       Date:  2012-06-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.